1. Academic Validation
  2. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

  • Nat Cancer. 2022 Apr;3(4):402-417. doi: 10.1038/s43018-022-00351-8.
Ciric To  # 1 2 3 Tyler S Beyett  # 4 5 Jaebong Jang  # 4 5 6 William W Feng 1 2 3 Magda Bahcall 1 2 3 Heidi M Haikala 1 2 3 Bo H Shin 1 2 3 David E Heppner 4 5 7 Jaimin K Rana 4 5 Brittaney A Leeper 8 Kara M Soroko 8 Michael J Poitras 8 Prafulla C Gokhale 8 Yoshihisa Kobayashi 1 2 3 9 Kamal Wahid 10 Kari J Kurppa 1 2 3 10 Thomas W Gero 4 5 Michael D Cameron 11 Atsuko Ogino 1 2 3 Mierzhati Mushajiang 1 2 3 Chunxiao Xu 1 2 3 Yanxi Zhang 1 2 3 David A Scott 12 13 Michael J Eck 14 15 Nathanael S Gray 16 17 18 Pasi A Jänne 19 20 21
Affiliations

Affiliations

  • 1 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • 3 Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • 4 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • 5 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • 6 College of Pharmacy, Korea University, Sejong, Korea.
  • 7 Department of Chemistry, University at Buffalo, Buffalo, NY, USA.
  • 8 Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.
  • 9 Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.
  • 10 Institute of Biomedicine, MediCity Research Laboratories, University of Turku, Turku, Finland.
  • 11 Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA.
  • 12 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
  • 13 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. [email protected].
  • 14 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
  • 15 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. [email protected].
  • 16 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
  • 17 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. [email protected].
  • 18 Department of Medicinal Chemistry and Department of Chemistry and Systems Biology, Stanford University, Stanford, CA, USA. [email protected].
  • 19 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
  • 20 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
  • 21 Department of Medicine, Harvard Medical School, Boston, MA, USA. [email protected].
  • # Contributed equally.
Abstract

Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant lung Cancer, although drug resistance eventually develops. Allosteric EGFR inhibitors, which bind to a different EGFR site than existing ATP-competitive EGFR TKIs, have been developed as a strategy to overcome therapy-resistant EGFR mutations. Here we identify and characterize JBJ-09-063, a mutant-selective allosteric EGFR inhibitor that is effective across EGFR TKI-sensitive and resistant models, including those with EGFR T790M and C797S mutations. We further uncover that EGFR homo- or heterodimerization with other ERBB family members, as well as the EGFR L747S mutation, confers resistance to JBJ-09-063, but not to ATP-competitive EGFR TKIs. Overall, our studies highlight the potential clinical utility of JBJ-09-063 as a single agent or in combination with EGFR TKIs to define more effective strategies to treat EGFR-mutant lung Cancer.

Figures
Products